Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 16
TP53 Mutant Variant Allele Frequency and Cytogenetics Determine Prognostic Groups in MDS/AML for Transplantation
Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal‐Shamanna, et al.
Blood Advances (2025)
Open Access | Times Cited: 1
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Amos Tuval, Charlotte Strandgren, Angelos Heldin, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 106-120
Closed Access | Times Cited: 39
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
Brunangelo Falini, Maria Paola Martelli
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 481-492
Closed Access | Times Cited: 34
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ehab Atallah, Rory M. Shallis, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 799-806
Open Access | Times Cited: 30
Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
Jayakumar Vadakekolathu, Sergio Rutella
Blood (2023) Vol. 143, Iss. 26, pp. 2689-2700
Open Access | Times Cited: 29
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Álex Bataller, Alexandre Bazinet, Courtney D. DiNardo, et al.
Blood Advances (2023) Vol. 8, Iss. 4, pp. 927-935
Open Access | Times Cited: 29
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
Jinze Shen, Qurui Wang, Yunan Mao, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Pathophysiology of Acute Myeloid Leukemia
Franziska Wachter, Yana Pikman
Acta Haematologica (2024) Vol. 147, Iss. 2, pp. 229-246
Closed Access | Times Cited: 10
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Jan Mueller, Roman R. Schimmer, Christian Koch, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 3, pp. 445-474
Open Access | Times Cited: 8
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia
Hiroki Akiyama, Bing Z. Carter, Michael Andreeff, et al.
Cells (2023) Vol. 12, Iss. 8, pp. 1128-1128
Open Access | Times Cited: 20
p53 biology and reactivation for improved therapy in MDS and AML
Joanna Zawacka‐Pankau
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Álex Bataller, Hagop M. Kantarjian, Alexandre Bazinet, et al.
Haematologica (2024)
Open Access | Times Cited: 5
TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
Davidson Zhao, Mojgan Zarif, Qianghua Zhou, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3210-3210
Open Access | Times Cited: 14
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Joseph G.W. McCarter, David Nemirovsky, Christopher Famulare, et al.
Blood Advances (2023) Vol. 7, Iss. 17, pp. 5000-5013
Open Access | Times Cited: 13
Prognostic impact of ‘multi-hit’ <i>versus</i> ‘single hit’ <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Haematologica (2024)
Open Access | Times Cited: 4
The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes
Wei Wang, Yudi Zhang, Wenli Yang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Navigating Cytomegalovirus Retinitis in a Patient With Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia Post Transplant: A Case Study
Steven A Benyahia, Sunny Kahlon, Srijit Paul, et al.
Cureus (2025)
Open Access
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block
Jiexian Ma, Shunrong Sun, Yanhui Xie, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53
Nour Sabiha Naji, Sergiu Pașca, Theodora Chatzilygeroudi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Saubia Fathima, Maymona Abdelmagid, Ali Alsugair, et al.
American Journal of Hematology (2025)
Closed Access
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Jayastu Senapati, Tapan M. Kadia, Naval Daver, et al.
Cancer (2025) Vol. 131, Iss. 7
Closed Access
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Carlos Jiménez‐Vicente, Jordi Esteve, Mónica Baile-González, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion
Naval Daver, Shahed Iqbal, Julie Huang, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1176-1184
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top